The provided study investigates the potential of the common antiparasitic medication mebendazole as a novel treatment for human cancer. The authors discovered that mebendazole successfully arrests cancer cell division by disrupting internal cellular scaffolds and triggering programmed cell death. Furthermore, experiments in living subjects showed that this medication strongly inhibits tumor growth and limits lung cancer spread without significantly harming healthy tissues. Ultimately, the research highlights how mebendazole suppresses the formation of new blood vessels that feed tumors, suggesting it could be a remarkably safe and effective therapy for various malignancies. This article discusses in vitro and in vivo preclinical testing (lab & animal).
In preclinical models, mebendazole (MZ) exerts potent, multi-faceted antitumor and anti-angiogenic effects while maintaining exceptional selectivity for malignant cells.
1. In Vitro Cytotoxicity & High Selectivity
Potent Growth Inhibition: Mebendazole induces dose- and time-dependent growth inhibition across human non-small cell lung cancer lines (A549, H1299, H460) with a half-maximal inhibitory concentration (IC50) of ~0.16 µM, suppressing cell growth 5-fold over 5 days.
Broad Spectrum Efficacy: Beyond lung cancer, mebendazole displays strong antiproliferative activity against breast, ovarian, and colorectal carcinomas as well as osteosarcomas (IC50 ranging from 0.1 to 0.8 µM).
Selectivity for Malignant Cells: Mebendazole demonstrates remarkable tumor selectivity, causing minimal to no toxicity in normal human umbilical vein endothelial cells (HUVECs) or normal WI38 lung fibroblasts, even at concentrations up to 1 µM.
2. Cell Cycle Arrest & Apoptotic Pathways
G2/M Phase Arrest: Mebendazole disrupts normal microtubule dynamics, trapping dividing tumor cells in G2/M phase arrest within 12 hours of exposure, before apoptosis begins.
Mitochondrial Cytochrome c Release: Mebendazole triggers cytochrome c release from mitochondria into the cytosol in both p53 wild-type (H460) and p53-null (H1299) cancer cells.
Caspase Activation & p53 Stabilization: Cytochrome c leakage initiates downstream apoptotic cascades—activating caspase-9 and caspase-8, cleaving procaspase-3 and PARP, and inducing internucleosomal DNA fragmentation. It also stabilizes the p53 tumor suppressor protein post-translationally, upregulating p53 target genes p21 and MDM2.
3. In Vivo Tumor Suppression & Anti-Angiogenesis
Xenograft Regression: In athymic nude (nu/nu) mice bearing established H460 lung cancer xenografts and C3H mice bearing syngeneic K1735 tumors, oral mebendazole (1 mg every other day) markedly suppressed tumor volume and tumor weight without causing systemic toxicity.
Disruption of Tumor Neovascularization: Mebendazole significantly reduced tumor vessel density, as shown by a sharp decrease in CD31-positive endothelial cells and a 75% reduction in intratumoral hemoglobin content.
Blockade of Capillary Formation: In dorsal air sac assays, mebendazole directly inhibited tumor-induced capillary vessel formation and branching.
4. Suppression of Distant Metastases
Experimental Lung Metastasis: In an in vivo tail-vein injection model using A549 lung cancer cells, oral mebendazole (1 mg twice weekly for 3 weeks) reduced the mean number of metastatic lung colonies by 80% (P<0.0001) and significantly decreased individual colony sizes. In contrast, paclitaxel monotherapy did not significantly reduce lung colony formation in this model.
(Note: While early landmark studies established mebendazole’s preclinical proof of concept, human clinical trials have since begun across various high-grade gliomas, gastrointestinal cancers, and pediatric brain tumors to evaluate its therapeutic efficacy in patient populations.)
Several Phase 1 and Phase 2 clinical trials are investigating repurposed benzimidazoles—primarily mebendazole (MBZ) and albendazole (ABZ)—as single agents or in combination with standard-of-care therapies:
Benzimidazole Clinical Trials
1. High-Grade Gliomas & Glioblastoma (GBM)
Adult Glioblastoma (Phase 1/2): Clinical trials (including those at Johns Hopkins University) are evaluating oral mebendazole combined with standard-of-care temozolomide (TMZ) and radiation therapy in newly diagnosed or recurrent glioblastoma.
Key Rationale: Mebendazole (specifically polymorphs B and C) crosses the blood–brain barrier to reach therapeutic intracranial concentrations without causing the severe peripheral neuropathy associated with vincristine.
2. Pediatric Central Nervous System (CNS) Tumors
Refractory CNS Malignancies (Phase 1): Phase 1 trials are assessing mebendazole safety, maximum tolerated dose (MTD), and pharmacokinetics in pediatric patients with recurrent or refractory medulloblastoma, high-grade gliomas, and other brain tumors.
3. Gastrointestinal & Colorectal Cancers
Metastatic Colorectal Cancer (Phase 2): Clinical protocols are testing mebendazole alone or alongside fluoropyrimidine- and oxaliplatin-based chemotherapy in advanced gastrointestinal carcinomas.
Mechanisms Targeted: These trials build on mebendazole’s ability to inhibit tumor angiogenesis (reducing CD31+ vessel density and VEGF), induce G2/M cell cycle arrest, and downregulate HIF-1α hypoxic response signatures.
4. Advanced & Refractory Solid Tumors
Combination Strategies (Phase 1/2): Trials are exploring mebendazole in combination with chemotherapy, immune checkpoint inhibitors, or other repurposed agents in treatment-refractory solid tumors, including triple-negative breast cancer, adrenocortical carcinoma, and stage IV melanoma.
5. Status of Fenbendazole in Human Trials
Unlike mebendazole and albendazole, which have extensive histories of FDA approval for human anthelmintic use, fenbendazole remains an unapproved veterinary agent. Consequently, formal human clinical trials for fenbendazole are lacking; evidence for fenbendazole relies on preclinical cell line/xenograft models and observational human case reports.
Mukhopadhyay, T., Sasaki, J., Ramesh, R., & Roth, J. A. (2002). Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clinical Cancer Research, 8(9), 2963–2969.
Thank you so much!